<sup>18</sup>F-NaF and <sup>18</sup>F-FDG as molecular probes in the evaluation of atherosclerosis.
review · Level V
Where this comes from
- Record sourced from PubMed, PMID 29978245.
- Also identified by DOI 10.1007/s00259-018-4078-0 and PMC identifier 6182398.
- Licence recorded as CC BY.
- The licence permits redistribution, so the abstract is shown in full and the full text is available from the publisher.
Abstract
The early detection of atherosclerotic disease is vital to the effective prevention and management of life-threatening cardiovascular events such as myocardial infarctions and cerebrovascular accidents. Given the potential for positron emission tomography (PET) to visualize atherosclerosis earlier in the disease process than anatomic imaging modalities such as computed tomography (CT), this application of PET imaging has been the focus of intense scientific inquiry. Although <sup>18</sup>F-FDG has historically been the most widely studied PET radiotracer in this domain, there is a growing body of evidence that <sup>18</sup>F-NaF holds significant diagnostic and prognostic value as well. In this article, we review the existing literature on the application of <sup>18</sup>F-FDG and <sup>18</sup>F-NaF as PET probes in atherosclerosis and present the findings of original animal and human studies that have examined how well <sup>18</sup>F-NaF uptake correlates with vascular calcification and cardiovascular risk.
Medical subject headings
- Atherosclerosis
- Fluorodeoxyglucose F18
- Positron-Emission Tomography
- Sodium Fluoride